

Robert Biesen

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2602588/publications.pdf>

Version: 2024-02-01

46
papers

1,647
citations

331670

21
h-index

315739

38
g-index

53
all docs

53
docs citations

53
times ranked

2320
citing authors

#	ARTICLE	IF	CITATIONS
1	Targeting CD38 with Daratumumab in Refractory Systemic Lupus Erythematosus. <i>New England Journal of Medicine</i> , 2020, 383, 1149-1155.	27.0	178
2	Sialic acid-binding Ig-like lectin 1 expression in inflammatory and resident monocytes is a potential biomarker for monitoring disease activity and success of therapy in systemic lupus erythematosus. <i>Arthritis and Rheumatism</i> , 2008, 58, 1136-1145.	6.7	163
3	CXCR3+CD4+ T cells are enriched in inflamed kidneys and urine and provide a new biomarker for acute nephritis flares in systemic lupus erythematosus patients. <i>Arthritis and Rheumatism</i> , 2009, 60, 199-206.	6.7	137
4	IFN- λ and its response proteins, IP-10 and SIGLEC-1, are biomarkers of disease activity in systemic lupus erythematosus. <i>Annals of the Rheumatic Diseases</i> , 2013, 72, 1639-1645.	0.9	115
5	Cell-Specific Type I IFN Signatures in Autoimmunity and Viral Infection: What Makes the Difference?. <i>PLoS ONE</i> , 2013, 8, e83776.	2.5	82
6	The multifaceted balance of TNF- λ and type I/II interferon responses in SLE and RA: how monocytes manage the impact of cytokines. <i>Journal of Molecular Medicine</i> , 2012, 90, 1295-1309.	3.9	67
7	Urinary CD4 T cells identify SLE patients with proliferative lupus nephritis and can be used to monitor treatment response. <i>Annals of the Rheumatic Diseases</i> , 2014, 73, 277-283.	0.9	60
8	Proteasome inhibition with bortezomib induces a therapeutically relevant depletion of plasma cells in SLE but does not target their precursors. <i>European Journal of Immunology</i> , 2018, 48, 1573-1579.	2.9	57
9	The protein tyrosine phosphatase PTP1B is a negative regulator of CD40 and BAFF-R signaling and controls B cell autoimmunity. <i>Journal of Experimental Medicine</i> , 2014, 211, 427-440.	8.5	51
10	Are interferon-related biomarkers advantageous for monitoring disease activity in systemic lupus erythematosus? A longitudinal benchmark study. <i>Rheumatology</i> , 2017, 56, 1618-1626.	1.9	49
11	Blood dendritic cells in systemic lupus erythematosus exhibit altered activation state and chemokine receptor function. <i>Annals of the Rheumatic Diseases</i> , 2010, 69, 1370-1377.	0.9	48
12	The cellular signature of urinary immune cells in Lupus nephritis: new insights into potential biomarkers. <i>Arthritis Research and Therapy</i> , 2015, 17, 94.	3.5	48
13	CD169/SIGLEC1 is expressed on circulating monocytes in COVID-19 and expression levels are associated with disease severity. <i>Infection</i> , 2021, 49, 757-762.	4.7	47
14	Antibodies against chemokine receptors CXCR3 and CXCR4 predict progressive deterioration of lung function in patients with systemic sclerosis. <i>Arthritis Research and Therapy</i> , 2018, 20, 52.	3.5	44
15	SIGLEC1 is a biomarker of disease activity and indicates extraglandular manifestation in primary Sjögren's syndrome. <i>RMD Open</i> , 2016, 2, e000292.	3.8	42
16	Choose wisely: imaging for diagnosis of axial spondyloarthritis. <i>Annals of the Rheumatic Diseases</i> , 2022, 81, 237-242.	0.9	38
17	Anti-dsDNA-NcX ELISA: dsDNA-loaded nucleosomes improve diagnosis and monitoring of disease activity in systemic lupus erythematosus. <i>Arthritis Research and Therapy</i> , 2011, 13, R26.	3.5	33
18	Pausing methotrexate improves immunogenicity of COVID-19 vaccination in elderly patients with rheumatic diseases. <i>Annals of the Rheumatic Diseases</i> , 2022, 81, 881-888.	0.9	33

#	ARTICLE	IF	CITATIONS
19	From transcriptome to cytome: Integrating cytometric profiling, multivariate cluster, and prediction analyses for a phenotypical classification of inflammatory diseases. <i>Cytometry Part A: the Journal of the International Society for Analytical Cytology</i> , 2008, 73A, 333-340.	1.5	28
20	Mapping urinary chemokines in human lupus nephritis: Potentially redundant pathways recruit CD4 ⁺ and CD8 ⁺ T cells and macrophages. <i>European Journal of Immunology</i> , 2017, 47, 180-192.	2.9	26
21	Nuclear antigen-reactive CD4 ⁺ T cells expand in active systemic lupus erythematosus, produce effector cytokines, and invade the kidneys. <i>Kidney International</i> , 2021, 99, 238-246.	5.2	26
22	Optimising both disease control and glucocorticoid dosing is essential for bone protection in patients with rheumatic disease. <i>Annals of the Rheumatic Diseases</i> , 2022, 81, 1313-1322.	0.9	25
23	Successful BNT162b2 booster vaccinations in a patient with rheumatoid arthritis and initially negative antibody response. <i>Annals of the Rheumatic Diseases</i> , 2021, 80, 1361-1362.	0.9	21
24	SIGLEC1 (CD169) is a sensitive biomarker for the deterioration of the clinical course in childhood systemic lupus erythematosus. <i>Lupus</i> , 2020, 29, 1914-1925.	1.6	20
25	Dysregulated CD38 Expression on Peripheral Blood Immune Cell Subsets in SLE. <i>International Journal of Molecular Sciences</i> , 2021, 22, 2424.	4.1	20
26	Type I interferon as a biomarker in autoimmunity and viral infection: a leukocyte subset-specific analysis unveils hidden diagnostic options. <i>Journal of Molecular Medicine</i> , 2017, 95, 753-765.	3.9	19
27	Autoantibodies, complement and type I interferon as biomarkers for personalized medicine in SLE. <i>Lupus</i> , 2016, 25, 823-829.	1.6	18
28	Serum antibodies to human leucocyte antigen (HLA)-E, HLA-F and HLA-G in patients with systemic lupus erythematosus (SLE) during disease flares: Clinical relevance of HLA-F autoantibodies. <i>Clinical and Experimental Immunology</i> , 2016, 183, 326-340.	2.6	18
29	What is the clinical significance of anti-Sm antibodies in systemic lupus erythematosus? A comparison with anti-dsDNA antibodies and C3. <i>Clinical and Experimental Rheumatology</i> , 2017, 35, 598-606.	0.8	18
30	Diagnostic value and clinical laboratory associations of antibodies against recombinant ribosomal P0, P1 and P2 proteins and their native heterocomplex in a Caucasian cohort with systemic lupus erythematosus. <i>Arthritis Research and Therapy</i> , 2011, 13, R20.	3.5	16
31	Siglec-1-positive plasmacytoid dendritic cells (pDCs) in human peripheral blood: A semi-mature and myeloid-like subset imbalanced during protective and autoimmune responses. <i>Clinical Immunology</i> , 2016, 163, 42-51.	3.2	16
32	SIGLEC1 enables straightforward assessment of type I interferon activity in idiopathic inflammatory myopathies. <i>RMD Open</i> , 2022, 8, e001934.	3.8	16
33	Ultra-low-dose CT detects synovitis in patients with suspected rheumatoid arthritis. <i>Annals of the Rheumatic Diseases</i> , 2019, 78, 31-35.	0.9	14
34	SIGLEC1 (CD169): a marker of active neuroinflammation in the brain but not in the blood of multiple sclerosis patients. <i>Scientific Reports</i> , 2021, 11, 10299.	3.3	14
35	Observational study and brief analysis of diagnostic criteria in relapsing polychondritis. <i>Rheumatology International</i> , 2018, 38, 2095-2101.	3.0	12
36	Perfusion in hand arthritis on dynamic contrast-enhanced computed tomography: a randomized prospective study using MRI as a standard of reference. <i>Skeletal Radiology</i> , 2021, 50, 59-68.	2.0	7

#	ARTICLE	IF	CITATIONS
37	Evaluation of SIGLEC1 in the diagnosis of suspected systemic lupus erythematosus. <i>Rheumatology</i> , 2022, 61, 3396-3400.	1.9	5
38	Contrast-enhanced CT techniques and MRI perform equally well in arthritis imaging of the hand: a prospective diagnostic accuracy study. <i>European Radiology</i> , 2022, 32, 6376-6383.	4.5	3
39	The type 1 interferon signature: facts, fads and fallacies. <i>Annals of the Rheumatic Diseases</i> , 2011, 70, A24-A24.	0.9	2
40	Quantification of morning stiffness to assess disease activity and treatment effects in rheumatoid arthritis. <i>Rheumatology</i> , 2021, 60, 5282-5291.	1.9	2
41	Defining T helper (CD4) cell-specific disease signatures in active, inactive and autologous stem cell transplanted lupus patients by global gene expression profiling. <i>Annals of the Rheumatic Diseases</i> , 2012, 71, A51.2-A52.	0.9	0
42	A2.6â€¦Cell-Specific Type I IFN Signatures in Autoimmunity and Viral Infection: What Makes the Difference?. <i>Annals of the Rheumatic Diseases</i> , 2013, 72, A6.1-A6.	0.9	0
43	A8.16â€¦T helper lymphocytes and monocytes as biosensors of type I interferon responses in viral infection and autoimmunity. <i>Annals of the Rheumatic Diseases</i> , 2014, 73, A82.2-A82.	0.9	0
44	FRI0433â€¦EFFECTS OF DISEASE MODIFYING DRUGS ON BONE MINERAL DENSITY, FRACTURE INCIDENCE, BACK PAIN AND PHYSICAL ACTIVITY IN PATIENTS WITH PSORIASIS AND PSORIATIC ARTHRITIS. , 2019, , .		0
45	Granulomatous large vessel phlebitis in sarcoidosis. <i>Rheumatology</i> , 2021, 60, e432-e434.	1.9	0
46	Ultra-Low-Dose Computed Tomography Subtraction for the Detection of Synovitis in Patients with Inflammatory Joint Disease. <i>Seminars in Musculoskeletal Radiology</i> , 2019, 23, .	0.7	0